|1.||Guo, Feng: 3 articles (06/2008 - 02/2007)|
|2.||Letrent, Stephen P: 3 articles (06/2008 - 02/2007)|
|3.||Munster, Pamela N: 2 articles (06/2008 - 02/2007)|
|4.||Sharma, Amarnath: 2 articles (06/2008 - 11/2007)|
|5.||Gelmon, Karen: 2 articles (06/2008 - 02/2007)|
|6.||Tolcher, Anthony W: 2 articles (06/2008 - 02/2007)|
|7.||Britten, Carolyn D: 2 articles (06/2008 - 02/2007)|
|8.||Streller, F: 1 article (01/2014)|
|9.||Dobbelstein, M: 1 article (01/2014)|
|10.||Schulz, R: 1 article (01/2014)|
|1.||Breast Neoplasms (Breast Cancer)
10/15/2007 - "Here, we describe the effects of CP-724,714 in vitro and in vivo in human breast cancer models. "
04/01/2009 - "The major human hepatic uptake transporter, OATP1B1, and efflux transporters, multidrug resistance protein 1 (MDR1) and breast cancer resistance protein, were involved in hepatobiliary clearance of CP-724,714. "
01/01/2014 - "Inhibiting HER2 pharmacologically by Lapatinib (a dual HER2/epidermal growth factor receptor inhibitor) or CP724.714 (a specific HER2 inhibitor), or by knockdown via siRNA leads to inhibition of phosphoactivated Ser326 HSF1, and subsequently blocks the activity of the HSP90 chaperone machinery in HER2-overexpressing breast cancer lines. "
11/01/2007 - "Concentration-time data (n = 484) from 30 cancer patients receiving daily oral CP-724,714 at doses of 250 mg QD, 250 mg BID, 250 mg TID, and 400 mg BID in 21-day cycles in an open label First-in-Human dose-escalation study were evaluated. "
02/15/2007 - "First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors."
10/15/2007 - "or b.i.d.) of CP-724,714 inhibits the growth of erbB2-overexpressing tumors in athymic mice without overt adverse effects."
06/01/2008 - "Patients (n = 30) with advanced malignant HER2 positive solid tumors were enrolled in this open label dose-escalation study, and treated with daily oral dosing of CP-724,714 in 21-day cycles at the following dose levels: 250 mg QD, 250 mg BID, 400 mg BID, and 250 mg TID. "
04/01/2009 - "CP-724,714, a potent and selective orally active HER2 tyrosine kinase inhibitor, was discontinued from clinical development due to unexpected hepatotoxicity in cancer patients. "
|3.||Neoplasm Metastasis (Metastasis)
|3.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|4.||Small Interfering RNA (siRNA)
|5.||Epidermal Growth Factor Receptor (EGF Receptor)